August 23, 2016

Waltham, Mass.; Aug. 23, 2016 (Business Wire) — Frenova Renal Research, the world’s only drug and medical device contract clinical development services provider dedicated to renal research, announced today its opening of a new office location in downtown Durham, N.C., and the expansion of its U.S. field-based staff in New York, Illinois, North Carolina, Florida and Louisiana.

“Our new presence in Durham provides us with strategic access to a large pool of talented clinical research professionals to facilitate our growth and better serve our clients,” said Kurt Mussina, Frenova general manager. “Additionally, expanding our field-based staff across the country enables us to flexibly manage the increased demand for our services. These investments will allow us to continue to develop and deliver innovative approaches to clinical research with the promise of improving the lives of patients with chronic kidney disease,” Mussina said.

Earlier this year, Frenova announced F1RST Up, an exclusive alliance of research sites designed to initiate and enroll clinical studies dramatically faster than industry norms with just-in-time patient recruitment.

“Our expanded team and larger footprint, combined with F1RST Up and our exclusive access to Fresenius Medical Care North America’s world-class research and data assets, reaffirm Frenova’s leadership position in renal research,” added Mussina.

Frenova’s new Durham office is located in the Fowler Building, 410 Blackwell St., Suite 430. For more information, call 844.253.3773 or visit

About Frenova Renal Research
Frenova is the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research. As a Fresenius Medical Care North America company, Frenova manages a networked system of clinical research assets and resources including more than 200 principal investigators and over 400 research-experienced dialysis facilities. Frenova manages clinical trials in kidney and its adjacent disease areas and medical conditions. Frenova also offers clinical trial sponsors access to over 180,000 active dialysis dependent CKD patients and 400,000 active non-dialysis dependent CKD patients. For more information, visit

Back to News